Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 74
- Registration Number
- NCT04428281
- Locations
- 🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸UCLA Neuropsychiatric Institute, Los Angeles, California, United States
🇺🇸Rush Medical Center, Chicago, Illinois, United States
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT04426825
- Locations
- 🇨🇳
Sun Yet-sen University Cancer Center, Guangzhou City, China
🇨🇳Beijing Hospital; Internal Medicine-Oncology, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, China
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT04422210
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸Emory University, Atlanta, Georgia, United States
🇩🇰Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
- Conditions
- COVID-19 Pneumonia
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 649
- Registration Number
- NCT04409262
- Locations
- 🇪🇸
Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇺🇸Baylor Scott & White Medical Center - Irving, Irving, Texas, United States
🇧🇷Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia, Curitiba, PR, Brazil
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 270
- Registration Number
- NCT04408638
- Locations
- 🇩🇪
Universitaetsklinikum Regensburg, Regensburg, Germany
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳Tianjin Cancer Hospital, Tianjin, China
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- Conditions
- Castration-Resistant Prostatic Cancer
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT04404140
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇪🇸Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain
🇫🇷Centre Val Aurelle Paul Lamarque; Radiotherapie, Montpellier, France
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1382
- Registration Number
- NCT04374253
- Locations
- 🇺🇸
Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States
🇺🇸Brain Matters Research, Inc., Delray Beach, Florida, United States
🇺🇸Infinity Clinical Research, LLC, Sunrise, Florida, United States
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
- Conditions
- COVID-19 Pneumonia
- Interventions
- Drug: Tociliuzumab
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT04363736
- Locations
- 🇺🇸
St Joseph's Regional Medical Center, Wayne, New Jersey, United States
🇺🇸St. Jude Medical Center, Fullerton, California, United States
🇺🇸Advocate Christ Medical Center, Oak Lawn, Illinois, United States
A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT04341259
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai City, China
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 116
- Registration Number
- NCT04339413
- Locations
- 🇦🇷
Instituto Neurologia Bs As, Ciudad Autonoma Buenos Aires, Argentina
🇯🇵Juntendo University Urayasu Hospital; Neurology, Chiba, Japan
🇵🇱NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek, Pozna?, Poland